ZA200106584B - Triazole compounds with dopamine-D3-receptor affinity. - Google Patents

Triazole compounds with dopamine-D3-receptor affinity. Download PDF

Info

Publication number
ZA200106584B
ZA200106584B ZA200106584A ZA200106584A ZA200106584B ZA 200106584 B ZA200106584 B ZA 200106584B ZA 200106584 A ZA200106584 A ZA 200106584A ZA 200106584 A ZA200106584 A ZA 200106584A ZA 200106584 B ZA200106584 B ZA 200106584B
Authority
ZA
South Africa
Prior art keywords
phenyl
alkyl
compound
formula
halogen
Prior art date
Application number
ZA200106584A
Other languages
English (en)
Inventor
Dorothea Starck
Hans-Joerg Treiber
Liliane Unger
Barbara Neumann-Schultz
Kai Blumbach
Dietmar Schoebel
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA200106584B publication Critical patent/ZA200106584B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200106584A 1999-01-12 2001-08-10 Triazole compounds with dopamine-D3-receptor affinity. ZA200106584B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19900811 1999-01-12

Publications (1)

Publication Number Publication Date
ZA200106584B true ZA200106584B (en) 2002-08-12

Family

ID=7894006

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200106584A ZA200106584B (en) 1999-01-12 2001-08-10 Triazole compounds with dopamine-D3-receptor affinity.
ZA200106585A ZA200106585B (en) 1999-01-12 2001-08-10 Triazole compounds with dopamine-D3-receptor affinity.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200106585A ZA200106585B (en) 1999-01-12 2001-08-10 Triazole compounds with dopamine-D3-receptor affinity.

Country Status (28)

Country Link
US (3) US6602867B1 (cs)
EP (3) EP1140907B1 (cs)
JP (3) JP2002534521A (cs)
KR (3) KR100775720B1 (cs)
CN (3) CN1347414A (cs)
AR (3) AR022228A1 (cs)
AT (3) ATE366729T1 (cs)
AU (3) AU773047B2 (cs)
BG (2) BG65105B1 (cs)
BR (2) BR0007500A (cs)
CA (3) CA2359952A1 (cs)
CO (3) CO5150224A1 (cs)
CZ (2) CZ303926B6 (cs)
DE (3) DE50014472D1 (cs)
ES (2) ES2334326T3 (cs)
HK (1) HK1045311B (cs)
HR (1) HRP20010590A2 (cs)
HU (2) HUP0200522A3 (cs)
ID (2) ID29930A (cs)
IL (3) IL144136A0 (cs)
NO (2) NO20013444L (cs)
NZ (2) NZ512864A (cs)
PL (2) PL201889B1 (cs)
SK (2) SK9862001A3 (cs)
TR (2) TR200102026T2 (cs)
TW (1) TWI274750B (cs)
WO (3) WO2000042037A1 (cs)
ZA (2) ZA200106584B (cs)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
PL347237A1 (en) 1998-10-08 2002-03-25 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
EP1283199A4 (en) * 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
ES2298294T3 (es) * 2000-11-14 2008-05-16 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina utiles como modulares de los receptores d3 de dopamina (agentes antipsicoticos).
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
EP1456178A1 (en) * 2001-12-21 2004-09-15 Smithkline Beecham Plc 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
DE10304870A1 (de) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
EP1606633B1 (en) * 2003-03-17 2008-06-04 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3)
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
EP1687299A1 (en) * 2003-11-20 2006-08-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treamtment and/or prevention of disorders modulated by a ppar
KR20050054084A (ko) * 2003-12-03 2005-06-10 한국전자통신연구원 수신 환경에 기반한 위성 상태 데이터 분배 기능을 가지는위성관제 시스템 및 그 방법
PL1745040T3 (pl) * 2004-02-23 2010-05-31 Glaxo Group Ltd Pochodne azabicyklo(3.1.0)heksanu użyteczne jako modulatory receptorów dopaminowych D3
WO2005087764A1 (en) * 2004-03-08 2005-09-22 Glaxo Group Limited Tetrahydrobenzazepine derivatives as modulators of dopamine d3 receptors (antipsychotic agents)
WO2005090320A2 (en) * 2004-03-12 2005-09-29 Wyeth Triazole derivatives and method of using the same to treat hiv infections
GB0412314D0 (en) * 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
GB0413879D0 (en) * 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
GB0414795D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
CA2574827C (en) 2004-08-09 2013-05-07 Abbott Gmbh & Co. Kg 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
CA2577060A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
JP5049134B2 (ja) 2004-12-02 2012-10-17 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンd3受容体の調節に応答する障害の治療に好適なトリアゾール化合物
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
AU2006338265B2 (en) 2005-08-18 2011-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
JP5237807B2 (ja) 2005-08-22 2013-07-17 グラクソ グループ リミテッド ドーパミンd3受容体の調節因子としてのトリアゾール誘導体
WO2007028145A2 (en) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
KR101567608B1 (ko) * 2007-02-08 2015-11-09 신타 파마슈티칼스 코프. 암과 같은 증식성 질환의 치료에 유용한 트라이아졸 화합물
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
EP2354136B1 (en) 2008-10-10 2016-02-24 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Novel dopamine d3 receptor ligands and preparation and medical uses of the same
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
US9326955B2 (en) * 2008-10-31 2016-05-03 Loyola University Chicago Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions
EP2792678A1 (en) * 2009-12-22 2014-10-22 Cephalon, Inc. Tricyclic derivatives and their pharmaceutical use and compositions
WO2012124744A1 (ja) * 2011-03-14 2012-09-20 大正製薬株式会社 含窒素縮合複素環化合物
CN104364249B (zh) * 2012-05-30 2018-04-17 霍夫曼-拉罗奇有限公司 作为pde10抑制剂的三唑并化合物
RU2561063C1 (ru) * 2014-07-01 2015-08-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Способ коррекции неврологических нарушений при хронической алкогольной интоксикации
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
EP3634406B1 (en) * 2017-05-12 2023-09-06 Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US10941153B2 (en) * 2018-05-31 2021-03-09 Regents Of The University Of Minnesota Substituted phenethylamine derivatives
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338453A (en) * 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4408049A (en) 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
FR2601952B1 (fr) 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
JP3155276B2 (ja) 1991-05-20 2001-04-09 ファルマシア・アンド・アップジョン・カンパニー カルボキサミド−(1,2n)−カルボサイクリック−2−アミノテトラリン誘導体
CA2122820A1 (en) 1991-11-05 1993-05-13 Russell Donavan Cousins Endothelin receptor antagonists
FR2687146B1 (fr) 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0699069T3 (da) 1993-04-27 2002-05-27 Smithkline Beecham Corp Endothelinreceptorantagonister
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
FR2722194B1 (fr) 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent
DE4425144A1 (de) * 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
JP2941950B2 (ja) * 1994-11-23 1999-08-30 ニューロゲン コーポレイション 或る種の4−アミノメチル−2−置換イミダゾール誘導体および2−アミノメチル−4−置換イミダゾール誘導体;新規な種類のドーパミン リセプタ亜型特異性リガンド
EP0817767B1 (en) 1995-03-27 2000-05-24 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic agents
AU5272296A (en) 1995-04-06 1996-10-23 Novo Nordisk A/S Benzopyranopyrrole compounds, their preparation and use
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
JPH11515030A (ja) * 1995-11-10 1999-12-21 ノボ ノルディスク アクティーゼルスカブ シス−ベンズ[e]インドール化合物のエナンチオマー、これらの製造、及びドーパミン−D3受容体選択的医薬としての利用
FR2742149B1 (fr) 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
KR20000010905A (ko) * 1996-05-11 2000-02-25 피터 기딩스 도파민 d3 수용체의 조절제로서의 테트라히드로이소퀴놀린유도체
CZ370198A3 (cs) * 1996-05-31 1999-05-12 Pharmacia & Upjohn Company Aryl substituované cyklické aminy jako selektivní dopaminové D3 ligandy
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
ES2154470T3 (es) 1996-08-14 2001-04-01 Smithkline Beecham Plc Derivados de tetrahidroisoquinolina y su uso farmaceutico.
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
CN1130365C (zh) 1996-12-06 2003-12-10 艾博特公司 α-1肾上腺素能化合物,含有该化合物的药物组合物及其应用
FR2760014B1 (fr) * 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9708694D0 (en) * 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) * 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
IL132631A0 (en) * 1997-05-03 2001-03-19 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710366D0 (en) * 1997-05-20 1997-07-16 Biocompatibles Ltd Stent deployment device
FR2764890B1 (fr) * 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion

Also Published As

Publication number Publication date
KR100687682B1 (ko) 2007-02-28
AU772948B2 (en) 2004-05-13
HUP0200522A2 (en) 2002-06-29
JP2002534521A (ja) 2002-10-15
CZ20012551A3 (cs) 2002-03-13
CN1149209C (zh) 2004-05-12
TR200102025T2 (tr) 2002-05-21
HUP0200709A3 (en) 2004-07-28
PL349841A1 (en) 2002-09-23
CN1267430C (zh) 2006-08-02
WO2000042036A1 (de) 2000-07-20
NZ512830A (en) 2003-08-29
HK1045311A1 (en) 2002-11-22
WO2000042038A1 (de) 2000-07-20
CN1345318A (zh) 2002-04-17
PL201889B1 (pl) 2009-05-29
US6579892B1 (en) 2003-06-17
NO20013443D0 (no) 2001-07-11
AU2541200A (en) 2000-08-01
BG105783A (en) 2002-03-29
BG65086B1 (bg) 2007-02-28
ATE366729T1 (de) 2007-08-15
NZ512864A (en) 2003-04-29
PL200238B1 (pl) 2008-12-31
US6583166B1 (en) 2003-06-24
KR100775720B1 (ko) 2007-11-09
CA2359948A1 (en) 2000-07-20
EP1144405A1 (de) 2001-10-17
AR022229A1 (es) 2002-09-04
EP1140908A1 (de) 2001-10-10
CN1345319A (zh) 2002-04-17
WO2000042037A1 (de) 2000-07-20
NO20013443L (no) 2001-07-12
CN1347414A (zh) 2002-05-01
DE50015576D1 (de) 2009-04-16
KR20010086471A (ko) 2001-09-12
CO5150227A1 (es) 2002-04-29
KR20070032830A (ko) 2007-03-22
ES2334326T3 (es) 2010-03-09
EP1140908B1 (de) 2009-03-04
CO5150224A1 (es) 2002-04-29
AU773047B2 (en) 2004-05-13
IL144137A0 (en) 2002-05-23
AU2436700A (en) 2000-08-01
BG65105B1 (bg) 2007-02-28
PL350246A1 (en) 2002-12-02
KR100730667B1 (ko) 2007-06-21
ZA200106585B (en) 2002-08-12
TWI274750B (en) 2007-03-01
DE50014472D1 (de) 2007-08-23
CA2359948C (en) 2010-09-21
CA2359952A1 (en) 2000-07-20
IL144136A (en) 2006-12-10
JP2002534519A (ja) 2002-10-15
IL144136A0 (en) 2002-05-23
CO5150182A1 (es) 2002-04-29
CZ20012550A3 (cs) 2002-02-13
NO20013444D0 (no) 2001-07-11
BR0007504A (pt) 2001-10-02
EP1144405B1 (de) 2009-11-25
CA2359942A1 (en) 2000-07-20
KR20010086470A (ko) 2001-09-12
BR0007500A (pt) 2001-10-23
AR022230A1 (es) 2002-09-04
BG105784A (en) 2002-02-28
JP2002534520A (ja) 2002-10-15
NO20013444L (no) 2001-07-11
JP4615125B2 (ja) 2011-01-19
SK9852001A3 (en) 2002-04-04
HUP0200522A3 (en) 2003-05-28
JP4933694B2 (ja) 2012-05-16
EP1140907B1 (de) 2007-07-11
ID29930A (id) 2001-10-25
HK1045311B (zh) 2007-03-30
US6602867B1 (en) 2003-08-05
AU2289700A (en) 2000-08-01
DE50015802D1 (de) 2010-01-07
AR022228A1 (es) 2002-09-04
SK9862001A3 (en) 2002-04-04
ATE424398T1 (de) 2009-03-15
HRP20010590A2 (en) 2003-08-31
ID29552A (id) 2001-09-06
EP1140907A1 (de) 2001-10-10
ATE449768T1 (de) 2009-12-15
ES2288839T3 (es) 2008-02-01
HUP0200709A2 (hu) 2002-07-29
CZ303926B6 (cs) 2013-06-26
TR200102026T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
ZA200106584B (en) Triazole compounds with dopamine-D3-receptor affinity.
DE60132235T2 (de) Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
US6593322B1 (en) Compounds and methods for modulation of estrogen receptors
WO2005058837A1 (en) Benzazepine derivatives as histamine h3 antagonists
PL220722B1 (pl) Benzoazepinowe pochodne, zawierająca je kompozycja farmaceutyczna i ich zastosowania do wytwarzania leku i do leczenia chorób neurologicznych
CN102448961A (zh) 作为用于治疗生育力病症的fsh受体激动剂的(二氢)咪唑并异[5,1-a]喹啉
KR20110120939A (ko) 디아제핀디온 유도체
CN103201270B (zh) P2x4受体拮抗剂
PL211340B1 (pl) Pochodne (imidazol-1-ilometylo)pirydazyny, lek zawierający te pochodne, sposób wytwarzania i zastosowanie tych pochodnych
KR20150011838A (ko) 탄키라아제 억제제로서의 피롤로피라존
WO2009092276A1 (zh) 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
US6900214B2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20030008888A1 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP2501233B1 (en) Quinazoline compounds
KR20010015787A (ko) 테트라히드로피리도피리미디논의 제3 위치 치환 유도체,그의 제조 방법 및 용도
KR101082227B1 (ko) 피라졸로피리미딘 화합물의 메탄술폰산염, 그 결정 및 그제조 방법
EP2632919A2 (en) Pyrazole compounds
JP3786985B2 (ja) ピロリジノン誘導体
MXPA01006840A (en) Triazole compounds with dopamine-d3-receptor affinity
TW202416958A (zh) 用於抑制yap-tead交互作用的新穎雜雙環化合物及包含其之藥學組成物
MXPA00002601A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use